perampanel Articles
Eisai re-submits perampanel NDA; FDA accepts Gilead’s Quad
28 December 2011
Eisai epilepsy drug delayed by US FDA, but Zonegran use extension filing accepted in EU
1 August 2011
Eisai Ph III study for eritoran fails to meet primary endpoint, but perampanel filing due this quarter
26 January 2011
Showing 1-7 of 7 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
